4.7 Article

Intrathecal Injection of the Secretome from ALS Motor Neurons Regulated for miR-124 Expression Prevents Disease Outcomes in SOD1-G93A Mice

期刊

BIOMEDICINES
卷 10, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines10092120

关键词

ALS mouse model; anti-microRNA-124; intraspinal delivery route; neuroprotection; prevention of glial dysfunction; preservation of motor performance; secretome-based therapy; SOD1-G93A mutation

资金

  1. Santa Casa da Misericordia de Lisboa [ELA-2015-002]
  2. Fundacao para a Ciencia e a Tecnologia (FCT) [PTDC/MED-NEU/31395/2017, UIDB/UIDP/04138/2020, UID/DTP/04138/2019-2020]
  3. Programa Operacional Regional de Lisboa
  4. Programa Operacional Competitividade e Internacionalizacao [LISBOA-01-0145-FEDER-031395]
  5. La Caixa Foundation
  6. Francisco Luzon Foundation [HR21-00931]
  7. FCT [SFRH/BD/129586/2017]
  8. ICVS Scientific Microscopy Platform of the national infrastructure of PPBI-Portuguese Platform of Bioimaging [PPBI-POCI-01-0145-FEDER-022122]

向作者/读者索取更多资源

The intrathecal administration of the secretome from anti-miR-124-treated mSOD1 MNs is a potential therapeutic strategy for halting/delaying disease progression in an ALS mouse model. It prevents motor impairment, muscle atrophy, glial reactivity/dysfunction, and neurodegeneration, while regulating gene expression and inflammatory miRNAs.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with short life expectancy and no effective therapy. We previously identified upregulated miR-124 in NSC-34-motor neurons (MNs) expressing human SOD1-G93A (mSOD1) and established its implication in mSOD1 MN degeneration and glial cell activation. When anti-miR-124-treated mSOD1 MN (preconditioned) secretome was incubated in spinal cord organotypic cultures from symptomatic mSOD1 mice, the dysregulated homeostatic balance was circumvented. To decipher the therapeutic potential of such preconditioned secretome, we intrathecally injected it in mSOD1 mice at the early stage of the disease (12-week-old). Preconditioned secretome prevented motor impairment and was effective in counter-acting muscle atrophy, glial reactivity/dysfunction, and the neurodegeneration of the symptomatic mSOD1 mice. Deficits in corticospinal function and gait abnormalities were precluded, and the loss of gastrocnemius muscle fiber area was avoided. At the molecular level, the preconditioned secretome enhanced NeuN mRNA/protein expression levels and the PSD-95/TREM2/IL-10/arginase 1/MBP/PLP genes, thus avoiding the neuronal/glial cell dysregulation that characterizes ALS mice. It also prevented upregulated GFAP/Cx43/S100B/vimentin and inflammatory-associated miRNAs, specifically miR-146a/miR-155/miR-21, which are displayed by symptomatic animals. Collectively, our study highlights the intrathecal administration of the secretome from anti-miR-124-treated mSOD1 MNs as a therapeutic strategy for halting/delaying disease progression in an ALS mouse model.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据